vs
Side-by-side financial comparison of Charles River Laboratories (CRL) and Gilead Sciences (GILD). Click either name above to swap in a different company.
Gilead Sciences is the larger business by last-quarter revenue ($7.9B vs $994.2M, roughly 8.0× Charles River Laboratories). Gilead Sciences runs the higher net margin — 27.5% vs -27.8%, a 55.4% gap on every dollar of revenue. On growth, Gilead Sciences posted the faster year-over-year revenue change (4.7% vs -0.8%). Gilead Sciences produced more free cash flow last quarter ($3.1B vs $58.6M). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs -0.9%).
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
CRL vs GILD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $994.2M | $7.9B |
| Net Profit | $-276.6M | $2.2B |
| Gross Margin | — | 79.5% |
| Operating Margin | -28.5% | 25.0% |
| Net Margin | -27.8% | 27.5% |
| Revenue YoY | -0.8% | 4.7% |
| Net Profit YoY | -28.9% | 22.4% |
| EPS (diluted) | $-5.57 | $1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $994.2M | $7.9B | ||
| Q3 25 | $1.0B | $7.8B | ||
| Q2 25 | $1.0B | $7.1B | ||
| Q1 25 | $984.2M | $6.7B | ||
| Q4 24 | $1.0B | $7.6B | ||
| Q3 24 | $1.0B | $7.5B | ||
| Q2 24 | $1.0B | $7.0B | ||
| Q1 24 | $1.0B | $6.7B |
| Q4 25 | $-276.6M | $2.2B | ||
| Q3 25 | $54.4M | $3.1B | ||
| Q2 25 | $52.3M | $2.0B | ||
| Q1 25 | $25.5M | $1.3B | ||
| Q4 24 | $-214.5M | $1.8B | ||
| Q3 24 | $69.7M | $1.3B | ||
| Q2 24 | $94.1M | $1.6B | ||
| Q1 24 | $73.0M | $-4.2B |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 79.8% | ||
| Q2 25 | — | 78.8% | ||
| Q1 25 | — | 76.9% | ||
| Q4 24 | — | 79.1% | ||
| Q3 24 | 34.6% | 79.1% | ||
| Q2 24 | 34.5% | 77.8% | ||
| Q1 24 | 34.1% | 76.8% |
| Q4 25 | -28.5% | 25.0% | ||
| Q3 25 | 13.3% | 42.8% | ||
| Q2 25 | 9.7% | 34.9% | ||
| Q1 25 | 7.6% | 33.6% | ||
| Q4 24 | -16.7% | 32.4% | ||
| Q3 24 | 11.6% | 11.8% | ||
| Q2 24 | 14.8% | 38.0% | ||
| Q1 24 | 12.5% | -64.6% |
| Q4 25 | -27.8% | 27.5% | ||
| Q3 25 | 5.4% | 39.3% | ||
| Q2 25 | 5.1% | 27.7% | ||
| Q1 25 | 2.6% | 19.7% | ||
| Q4 24 | -21.4% | 23.6% | ||
| Q3 24 | 6.9% | 16.6% | ||
| Q2 24 | 9.2% | 23.2% | ||
| Q1 24 | 7.2% | -62.4% |
| Q4 25 | $-5.57 | $1.75 | ||
| Q3 25 | $1.10 | $2.43 | ||
| Q2 25 | $1.06 | $1.56 | ||
| Q1 25 | $0.50 | $1.04 | ||
| Q4 24 | $-4.17 | $1.43 | ||
| Q3 24 | $1.33 | $1.00 | ||
| Q2 24 | $1.74 | $1.29 | ||
| Q1 24 | $1.30 | $-3.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $213.8M | $68.0M |
| Total DebtLower is stronger | $2.1B | $24.9B |
| Stockholders' EquityBook value | $3.2B | $22.7B |
| Total Assets | $7.1B | $59.0B |
| Debt / EquityLower = less leverage | 0.68× | 1.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $213.8M | $68.0M | ||
| Q3 25 | $207.1M | $19.0M | ||
| Q2 25 | $182.8M | $69.0M | ||
| Q1 25 | $229.4M | — | ||
| Q4 24 | $194.6M | — | ||
| Q3 24 | $210.2M | — | ||
| Q2 24 | $179.2M | — | ||
| Q1 24 | $327.0M | — |
| Q4 25 | $2.1B | $24.9B | ||
| Q3 25 | $2.2B | $24.9B | ||
| Q2 25 | $2.3B | $24.9B | ||
| Q1 25 | $2.5B | $25.0B | ||
| Q4 24 | $2.2B | $26.7B | ||
| Q3 24 | $2.3B | $23.2B | ||
| Q2 24 | $2.4B | $23.3B | ||
| Q1 24 | $2.7B | $25.2B |
| Q4 25 | $3.2B | $22.7B | ||
| Q3 25 | $3.4B | $21.5B | ||
| Q2 25 | $3.4B | $19.7B | ||
| Q1 25 | $3.2B | $19.2B | ||
| Q4 24 | $3.5B | $19.3B | ||
| Q3 24 | $3.8B | $18.5B | ||
| Q2 24 | $3.7B | $18.3B | ||
| Q1 24 | $3.6B | $17.5B |
| Q4 25 | $7.1B | $59.0B | ||
| Q3 25 | $7.5B | $58.5B | ||
| Q2 25 | $7.6B | $55.7B | ||
| Q1 25 | $7.6B | $56.4B | ||
| Q4 24 | $7.5B | $59.0B | ||
| Q3 24 | $8.0B | $54.5B | ||
| Q2 24 | $7.9B | $53.6B | ||
| Q1 24 | $8.2B | $56.3B |
| Q4 25 | 0.68× | 1.10× | ||
| Q3 25 | 0.64× | 1.16× | ||
| Q2 25 | 0.70× | 1.27× | ||
| Q1 25 | 0.79× | 1.30× | ||
| Q4 24 | 0.65× | 1.38× | ||
| Q3 24 | 0.62× | 1.26× | ||
| Q2 24 | 0.65× | 1.28× | ||
| Q1 24 | 0.73× | 1.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.5M | $3.3B |
| Free Cash FlowOCF − Capex | $58.6M | $3.1B |
| FCF MarginFCF / Revenue | 5.9% | 39.4% |
| Capex IntensityCapex / Revenue | 8.9% | 2.6% |
| Cash ConversionOCF / Net Profit | — | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | $518.5M | $9.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $147.5M | $3.3B | ||
| Q3 25 | $213.8M | $4.1B | ||
| Q2 25 | $204.6M | $827.0M | ||
| Q1 25 | $171.7M | $1.8B | ||
| Q4 24 | $159.4M | $3.0B | ||
| Q3 24 | $251.8M | $4.3B | ||
| Q2 24 | $193.5M | $1.3B | ||
| Q1 24 | $129.9M | $2.2B |
| Q4 25 | $58.6M | $3.1B | ||
| Q3 25 | $178.2M | $4.0B | ||
| Q2 25 | $169.3M | $720.0M | ||
| Q1 25 | $112.4M | $1.7B | ||
| Q4 24 | $83.7M | $2.8B | ||
| Q3 24 | $213.1M | $4.2B | ||
| Q2 24 | $154.0M | $1.2B | ||
| Q1 24 | $50.7M | $2.1B |
| Q4 25 | 5.9% | 39.4% | ||
| Q3 25 | 17.7% | 51.0% | ||
| Q2 25 | 16.4% | 10.2% | ||
| Q1 25 | 11.4% | 24.8% | ||
| Q4 24 | 8.4% | 37.4% | ||
| Q3 24 | 21.1% | 55.2% | ||
| Q2 24 | 15.0% | 17.2% | ||
| Q1 24 | 5.0% | 31.6% |
| Q4 25 | 8.9% | 2.6% | ||
| Q3 25 | 3.5% | 1.9% | ||
| Q2 25 | 3.4% | 1.5% | ||
| Q1 25 | 6.0% | 1.6% | ||
| Q4 24 | 7.5% | 1.9% | ||
| Q3 24 | 3.8% | 1.9% | ||
| Q2 24 | 3.8% | 1.9% | ||
| Q1 24 | 7.8% | 1.6% |
| Q4 25 | — | 1.52× | ||
| Q3 25 | 3.93× | 1.35× | ||
| Q2 25 | 3.91× | 0.42× | ||
| Q1 25 | 6.74× | 1.34× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | 3.61× | 3.44× | ||
| Q2 24 | 2.06× | 0.82× | ||
| Q1 24 | 1.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
